Indivina

Medroxyprogesterone acetate and estradiol valerate, the active ingredients in Indivina, are hormonal agents presented as oral tablets for systemic use. They are combined to provide estrogen‑progestogen therapy in women requiring hormone replacement.

GNH USA supplies Indivina as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Indivina combines medroxyprogesterone acetate and estradiol valerate to provide hormonal therapy for conditions related to estrogen deficiency.

- Menopausal symptom relief: reduces hot flashes, night sweats, and vaginal atrophy. - Osteoporosis prevention: helps maintain bone mineral density in postmenopausal women. - Hypoestrogenic states: restores estrogen levels in women with ovarian insufficiency.

Indivina may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Nausea - Breast tenderness - Headache - Weight gain - Mood changes - Irregular vaginal bleeding

Serious or Rare Side Effects: - Deep vein thrombosis or pulmonary embolism - Stroke or myocardial infarction - Severe liver dysfunction - Allergic reactions such as rash or angioedema - Visual disturbances - Unexplained abdominal pain

Before initiating therapy, clinicians should evaluate individual risk factors and monitor patients regularly.

- Assess thromboembolic risk: review personal or family history of clotting disorders. - Screen for cardiovascular disease: consider hypertension, smoking status, and lipid profile. - Monitor liver function: avoid use in severe hepatic impairment. - Contraindicated in estrogen‑dependent tumors: do not use in known breast or endometrial cancer. - Pregnancy and lactation: not recommended during pregnancy or while breastfeeding. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Indivina can interact with several drug classes; awareness of major and moderate interactions helps prevent adverse events.

Major Interactions (Avoid): - Combined oral anticoagulants: increased risk of thrombosis. - Selective serotonin reuptake inhibitors: may heighten bleeding tendency. - Strong CYP3A4 inhibitors (e.g., ketoconazole): raise hormone plasma levels. - CYP3A4 inducers (e.g., rifampicin): reduce hormonal efficacy. - Tamoxifen: antagonizes estrogenic effects.

Moderate Interactions (Monitor Closely): - Antihypertensives: possible alteration of blood pressure control. - Lithium: potential increase in lithium serum concentrations. - Carbamazepine: may lower hormone concentrations. - Phenobarbital: may diminish therapeutic effect. - St. John’s wort and other herbal inducers: could affect metabolism.